The importance of clinical grading of heart failure and other cardiac toxicities during chemotherapy: updating the common terminology criteria for clinical trial reporting
| Autor: | Wendy Taddei-Peters, Percy Ivy, Daniel J. Lenihan, Scot C. Remick, Jonathan Kaltman, Alice P. Chen, Akm Mosharraf Hossain |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
Drug-Related Side Effects and Adverse Reactions medicine.medical_treatment MEDLINE Antineoplastic Agents Cardiotoxins Risk Assessment Severity of Illness Index Targeted therapy Risk Factors Neoplasms Terminology as Topic Severity of illness medicine Humans Intensive care medicine Adverse effect Grading (tumors) business.industry Patient Selection Common Terminology Criteria for Adverse Events General Medicine medicine.disease Clinical trial Early Diagnosis Cardiovascular Diseases Medical emergency Cardiology and Cardiovascular Medicine business Risk assessment |
| Zdroj: | Heart failure clinics. 7(3) |
| ISSN: | 1551-7136 |
| Popis: | Although the use of chemotherapy and targeted therapy has improved the clinical benefit, progression-free survival, and overall survival of various cancers in recent years, old and new toxicities have limited their use. To balance the risk with the benefit of treatment, Common Toxicity Criteria and now Common Terminology Criteria for Adverse Events (CTCAE) have been used by the oncology community for more than 20 years to assess toxicity from cancer treatment. This article details the description and grading of cardiac toxicities reported in association with cancer treatment and the use of CTCAE to assess them. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|